arrow
B

Benjamin G. Bitler

university of colorado anschutz medical campus
H指数:38
被引数:5,619

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming

化疗诱导的衰老相关分泌组通过代谢重编程促进细胞脱离和转移性播散

2026-07-300
OA
Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer

邵, C.; Indeglia, A.; Foster, M.; Casey, K.; Leung, J.; Modarai, S.R.; Leu, J.I.-J.; Duong, B.; Mes-Masson, A.-M.; Sims-Mourtada, J.; 等. 突变P53与雌激素受体结合并调控其活性以驱动卵巢癌内分泌耐药. Genes Dev. 2025; epub ahead of print. [Google Scholar] [CrossRef] [PubMed]

2026-02-011
PRE
Bayesian multi-cell type models for the analysis of complex immune cell populations with application to ovarian cancer

基于贝叶斯的多细胞类型模型对复杂免疫细胞群体的分析及其在卵巢癌中的应用

2026-01-010
PRE
Clinical Evaluation of a Multi-Omic Diagnostic Model for Early-Stage Ovarian Cancer Detection

早期卵巢癌检测的多组学诊断模型的临床评估

2025-09-040
OA
A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer

一项关于rucaparib与安慰剂在转移性和复发性子宫内膜癌维持治疗中使用的II期、随机、双盲研究

2025-07-220
PRE
EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell-Dependent Manner
2024-08-130
PRE
Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation
2024-05-071
PRE